“Authorized Biosimilars” Could Be Priced at 50% of Originators: Prof.

Prof. Hiroyuki Sakamaki “Authorized biosimilars” (ABs) that are identical to originators in terms of manufacturing methods and facilities could be priced at 50% of the originals, just like first generics, instead of the current 70% rule for biosimilars in Japan,...read more